Precigen Aktie

1,42 EUR -0,04 EUR -2,75 %

15:58:39

FSE

1,65 USD -0,06 USD -3,52 %

17:18:27

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.441,61 Mio. EUR

Div. Rendite0,00%

WKNA2PZG1

ISINUS74017N1054

SymbolPGEN

Precigen Aktien News

Sortieren:Datum Meistgelesen

14.05.25PR NewswirePrecigen Reports First Quarter 2025 Financial Results and Business Updates

16.04.25PR NewswirePrecigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

20.03.25BenzingaExpert Outlook: Precigen Through The Eyes Of 4 Analysts

WerbungPrecigen-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

19.03.25ZacksPrecigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates

19.03.25PR NewswirePrecigen Reports Full Year 2024 Financial Results and Business Updates

13.03.25PR NewswirePrecigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

25.02.25PR NewswireFDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

20.02.25ZacksPrecigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?

13.01.25PR NewswirePrecigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

09.01.25PR NewswirePrecigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

30.12.24BenzingaPrecigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment

30.12.24PR NewswirePrecigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

14.11.24ZacksPrecigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates

14.11.24PR NewswirePrecigen Reports Third Quarter 2024 Financial Results and Business Updates

12.11.24PR NewswirePrecigen to Participate in the Stifel 2024 Healthcare Conference

16.09.24PR NewswirePrecigen to Participate in the 2024 Cantor Global Healthcare Conference

15.08.24BenzingaAssessing Precigen: Insights From 5 Financial Analysts

15.08.24BenzingaTitan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session

14.08.24ZacksPrecigen, Inc. (PGEN) Reports Q2 Loss, Misses Revenue Estimates

14.08.24PR NewswirePrecigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

09.08.24PR NewswirePrecigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

07.08.24ZacksEarnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline

06.08.24PR NewswirePrecigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

23.07.24PR NewswirePrecigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

03.06.24PR NewswirePrecigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

23.05.24PR NewswirePrecigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

14.05.24PR NewswirePrecigen Reports First Quarter 2024 Financial Results and Business Updates

08.05.24PR NewswirePrecigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

24.04.24PR NewswirePrecigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024...

24.04.24PR NewswireActym Therapeutics Appoints Thomas Smart as CEO

28.03.24PR NewswirePrecigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

19.03.24PR NewswirePrecigen Reports Full Year 2023 Financial Results and Business Updates

12.03.24PR NewswirePrecigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

05.03.24PR NewswirePrecigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

06.02.24PR NewswirePrecigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

16.01.24PR NewswirePrecigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

08.01.24PR NewswirePrecigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference

18.12.23PR NewswirePrecigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference

29.11.23PR NewswirePrecigen to Participate in the JMP Securities Hematology and Oncology Summit

09.11.23PR NewswirePrecigen Reports Third Quarter 2023 Financial Results and Progress of Clinical Programs

Precigen News

Precigen News: auf dieser Seite finden Sie alle Precigen News und Nachrichten zur Precigen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Precigen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Precigen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.